SGLT-2 inhibitors showed a good persistence of efficacy, at least up to 2 years, with a small but significant superiority over DPP-4i. Sulfonylureas are more effective in the very short term, but less effective in the longer term (Diabetes, Obesity and Metabolism)
Diabetes News
Tag: DPP-4i
Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study
Administration of DPP-4i reduces urine albumin excretion and mitigates reduction of eGFR in T2DM patients (Journal of Diabetes Research)
Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes
In patients with type 2 diabetes, there was no association between hHF, or other selected cardiovascular outcomes, and treatment with a DPP-4i relative to SU or treatment with saxagliptin relative to sitagliptin (Diabetes Care)
Glycosmedia is also available as an App: